Home >> General Pharmaceuticals >> Housing >> Food & Beverage >>

Xerostomia - Pipeline Review, H1 2015

Published: Jan-2015 | Format: PDF | Global Markets Direct | Number of pages: 41 | Code: MRS - 18127


Global Markets Directs, Xerostomia Pipeline Review, H1 2015, provides an overview of the Xerostomias therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Xerostomia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Xerostomia and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

The report provides a snapshot of the global therapeutic landscape of Xerostomia
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Xerostomia and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects 
A review of the Xerostomia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Xerostomia pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

Reasons to buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Xerostomia
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Xerostomia pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Xerostomia Overview 6
Therapeutics Development 7
Pipeline Products for Xerostomia - Overview 7
Pipeline Products for Xerostomia - Comparative Analysis 8
Xerostomia - Therapeutics under Development by Companies 9
Xerostomia - Therapeutics under Investigation by Universities/Institutes 10
Xerostomia - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Xerostomia - Products under Development by Companies 13
Xerostomia - Products under Investigation by Universities/Institutes 14
Xerostomia - Companies Involved in Therapeutics Development 15
Acacia Pharma Ltd. 15
Hadasit Medical Research Services & Development Ltd 16
Kadmon Corporation, LLC 17
Parion Sciences, Inc. 18
Xerostomia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
APD-515 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gene Therapy to Activate Aquaporin-1 for Xerostomia - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
HYPER-IL-6 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
P-552 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Xerostomia - Recent Pipeline Updates 35
Xerostomia - Dormant Projects 36
Xerostomia - Product Development Milestones 37
Featured News & Press Releases 37
Oct 15, 2013: Acacia Pharma Announces Positive Phase II Results With APD515 for Xerostomia in Advanced Cancer 37
Jul 25, 2011: Acacia Pharma Initiates Phase II Clinical Trial With APD515 For Xerostomia 38
Feb 07, 2011: Acacia Pharma Completes Phase I Clinical Trial With APD515 For Xerostomia 38
Jan 06, 2011: Acacia Pharma Starts Clinical Trial With APD515 In Xerostomia 39

Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41

List of Tables

Number of Products under Development for Xerostomia, H1 2015 7
Number of Products under Development for Xerostomia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Xerostomia - Pipeline by Acacia Pharma Ltd., H1 2015 15
Xerostomia - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2015 16
Xerostomia - Pipeline by Kadmon Corporation, LLC, H1 2015 17
Xerostomia - Pipeline by Parion Sciences, Inc., H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Xerostomia Therapeutics - Recent Pipeline Updates, H1 2015 35
Xerostomia - Dormant Projects, H1 2015 36

List of Figures

Number of Products under Development for Xerostomia, H1 2015 7
Number of Products under Development for Xerostomia - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Top 10 Targets, H1 2015 20
Number of Products by Stage and Top 10 Targets, H1 2015 21
Number of Products by Top 10 Mechanism of Actions, H1 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Top 10 Routes of Administration, H1 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25
Number of Products by Top 10 Molecule Types, H1 2015 26
Number of Products by Stage and Top 10 Molecule Types, H1 2015 27

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing